In 2022, Bausch Health Cos. and its GI business, Salix Pharmaceuticals, filed a lawsuit against Norwich alleging that the company infringed on Bausch’s patents for the drug Xifaxan.
A U.S. District Court of Delaware decision found that some of Bausch’s drug patents were infringed and invalid, and the company is currently appealing the decision to the U.S. Court of Appeals for the Federal Circuit.
By denying Norwich’s motion, the District Court granted judgment in favor of both the FDA and Salix, according to a Nov. 1 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
